Cemsidomide - C4 Therapeutics
Alternative Names: CFT 7455Latest Information Update: 09 Feb 2026
At a glance
- Originator C4 Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 29 Jan 2026 C4 Therapeutics initiates a phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT07280013)
- 12 Dec 2025 C4 Therapeutics plans a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT07280013)
- 06 Nov 2025 C4 Therapeutics plans a phase II MOMENTUM trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in the first quarter of 2026